Advectus Life Sciences Begins Preclinical Trials of P80DOX-NP

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 8
Volume 11
Issue 8

VANCOUVER, Canada-Ad-vectus Life Sciences Inc. has begun preclinical testing of its patented nanoparticle-based technology (Nanocure) at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure

VANCOUVER, Canada—Ad-vectus Life Sciences Inc. has begun preclinical testing of its patented nanoparticle-based technology (Nanocure) at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure formulation P80DOX-NP on rodent brain metastases arising from lung, breast, renal cell, and colon cancers, and melanoma, the company announced.

P80DOX-NP is a novel method for the delivery of doxorubicin across the blood-brain barrier. The randomized, placebo-controlled study will measure survival as a surrogate for intracranial tumor progression/regression.

Articles in this issue
Medicaid Gives New Protections to Beneficiaries in Managed Care Plans
Prostate Cancer Cell Line Vaccine Promising in Phase II Trial
MoAb Targeting Death Receptor in Breast Cancer
Hanford I-131 Releases Did Not Increase Thyroid Cancer Risk
Chemo/Rituximab Is Effective as First-Line CLL Therapy
Diagnostic Dilemma
Viral Agent ONYX-015 Targets p53-Deficient Cancer Cells
Program Educates Teens About Testicular Cancer Self-Exam
Better Colon Cancer Imaging With PET/CT Than With PET Alone
Delayed Lung Cancer Screening Trial to Begin Enrollment 50,000 Subjects
Results Similar With Weekly or Every-3-Week Irinotecan Dosing Regimens
Single-Dose Palonosetron Prevents Acute, Delayed Emesis
Adjuvant Chemo Controversy in Microsatellite Unstable Colon Cancer
Radiolabeled TNT MoAb Effective in Inoperable Lung Cancer
Multidetector CT Finds Peritoneal Ovarian Cancer Metastasis

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content
92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

Michelle Sosa;Deirdre McNicholas;Arbelina Bebla;Seth Emont;Zhun Cao;Manu Tyagi;Craig Lipkin;Sommer Gunia
April 19th 2025
Article
Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC

Roman Fabbricatore
April 18th 2025
Article

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

Classification System May Identify QOL Benefit with Palliative Radiotherapy

Roman Fabbricatore
April 18th 2025
Article

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

Tim Cortese
April 18th 2025
Article

Results from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin with chemotherapy in relapsed/refractory multiple myeloma.